POP MART
09992
XIAOMI-W
01810
BYD COMPANY
01211
4
MEITUAN-W
03690
5
BABA-W
09988
HK Stock MarketDetailed Quotes
01228 CANBRIDGE-B
- 0.149
- +0.007+4.93%
Not Open Apr 28 16:09 CST
63.30MMarket Cap-0.13P/E (TTM)
0.149High0.138Low623.00KVolume0.142Open0.142Pre Close88.54KTurnover0.15%Turnover RatioLossP/E (Static)424.84MShares0.50052wk High-0.12P/B63.30MFloat Cap0.09552wk Low--Dividend TTM424.84MShs Float9.990Historical High--Dividend LFY7.75%Amplitude0.095Historical Low0.142Avg Price1000Lot Size--Div YieldTTM--Div Yield LFY
CANBRIDGE-B News
CANBRIDGE-B (01228) released its annual performance, with a Shareholder attributable loss of 0.443 billion yuan, an increase of 16.84% year-on-year.
CANBRIDGE-B (01228) announced its annual results for the year ending December 31, 2024, with the group achieving revenues...
Express News | CANbridge Pharmaceuticals FY Gross Margin 63.8%
Express News | CANbridge Pharmaceuticals FY Adjusted Net Income RMB -346.9 Million
Express News | CANbridge Pharmaceuticals FY Revenue RMB 85.1 Million
Express News | CANbridge Pharmaceuticals FY Gross Profit RMB 54.3 Million
CANBRIDGE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
CANBRIDGE-B: POSTPONEMENT OF DATE OF BOARD MEETING
CANbridge Announces that Velaglucerase-beta for Injection Successfully Passed the Pre-approval inspection and Pre - marketing GMP Compliance Inpection for the Pilot Biological Product of Divided manuf
CANBRIDGE-B (01228.HK) plans to hold a Board of Directors meeting on March 28 to approve the annual performance.
Gelonghui announced on March 18 that CANBRIDGE-B (01228.HK) will hold a Board of Directors meeting on March 28, 2025 (Friday) to consider and approve the performance and its release for the year ending December 31, 2024 for the company and its subsidiaries.
CANBRIDGE-B: DATE OF BOARD MEETING
CANbridge Announces that Velaglucerase-beta for Injection Successfully Passed the Preapproval inspection & Premarketing GMP Compliance Inpection for Pilot Biological Product of Divided manufacturing
CANbridge Pharma Terminates Lease in Massachusetts Amid US Downsizing Efforts
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
North Sea Kang Cheng - B [01228] is currently reported at HKD 0.148, with an increase of 19.36%.
As of 11:57, Beihai Kangcheng - B [01228] is priced at 0.148 Hong Kong dollars, an increase of 0.024 Hong Kong dollars or 19.36% compared to yesterday's closing price of 0.124 Hong Kong dollars, with a trading volume of 0.0222 million Hong Kong dollars. Today's highest price is 0.148 Hong Kong dollars, and the lowest price is 0.132 Hong Kong dollars. Based on yesterday's closing price, the 10-day average price is 0.12 Hong Kong dollars, the 50-day average price is 0.15 Hong Kong dollars, and the current PE is -0.13 times, with a 14-day strength index of 42.98.
CANbridge Pharmaceuticals Inc.'s (HKG:1228) 25% Dip In Price Shows Sentiment Is Matching Revenues
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Beihai Kangcheng announced that Mai Ruibei for the treatment of PFIC cholestatic pruritus has been approved for sale in Taiwan.
Beihai Kangcheng announced that Mireb will be applicable to ALGS patient populations in Taiwan for more than 2 months.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.